Dublin, Feb. 12, 2024 (GLOBE NEWSWIRE) -- The "Drugs For Benign Prostatic hypertrophy Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.
Benign Prostatic Hypertrophy Drug Market Projections: Industry Growth Forecast to 2028
The global landscape of the benign prostatic hypertrophy (BPH) treatment market is advancing steadily, with projections indicating a rise in market value from $4.02 billion in 2023 to a potential high of $5.45 billion by 2028. A new in-depth research publication recently added to our comprehensive collection provides a rigorous analysis of this market, examining its historical trajectory, current trends, and future growth prospects. The robust expansion of the BPH drugs market at a steady compound annual growth rate (CAGR) of 6.0% is underpinned by an array of vital factors including demographic shifts, medical breakthroughs, and the rise of patient-centered care. As BPH predominantly affects the male population above the age of 50, the burgeoning global geriatric population is a significant catalyst for market growth. Growth Drivers and Industry Trends:
- With the escalation of chronic diseases among aging men, the need for effective BPH medications is set to surge. Our report offers comprehensive insights into the evolving dynamics that influence market expansion, highlighting the importance of innovative drug development and patient education.
- Emerging markets are poised to contribute significantly to the future market surge, offering fresh opportunities for medical suppliers and healthcare providers.
- A growing trend in bespoke patient therapies and the application of digital health solutions are shaping the way forward for BPH treatments.
- The utilization of combination drug therapies that improve patient outcomes while reducing side effects is gaining traction within the market.
Market Composition and Key Players: In terms of product types, the market is segmented into various drug classes such as alpha-blockers, 5-alpha reductase inhibitors, and more, with distribution channels encompassing hospital pharmacies, retail pharmacies, and online pharmacies alike. Leading entities in this sector are focusing on launching trailblazing drugs like Entadfi, which recently gained FDA approval, to capture a greater market share and improve patient care. Regional Insights: Significant Growth Anticipated in the Middle East BPH Drugs Market
While North America stands as the largest contributor in this space, the Middle East region is projected to emerge as the fastest-growing market for BPH drugs. This surge is due in part to increased healthcare investment, the adoption of modern medical practices, and a rising awareness of male health issues in the region. Our report diligently covers the intricate market landscapes across key regions including Asia-Pacific, Western Europe, Eastern Europe, South America, and Africa. Additionally, our analysis peels back the layers of market activity within pivotal nations such as Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, as well as the UK, USA, Italy, Spain, and Canada. The detailed report serves as an essential resource for stakeholders, investors, and industry players looking to navigate the complexities of the BPH drugs market, embracing its growth potential and responding proactively to the shifting terrain of global healthcare demands. For industry professionals, healthcare providers, and decision-makers, the comprehensive insights delivered within this new report are crucial for gaining an edge in the increasingly competitive BPH drug market space and for the strategy formulation needed for fostering enduring growth and market stability.
A selection of companies mentioned in this report includes
- Allergan Inc.
- Astellas Pharma Inc.
- Boehringer Ingelheim International GmbH
- GlaxoSmithKline plc
- Teva Pharmaceutical Industries Limited
- Sanofi S.A.
- Nymox Pharmaceutical Corporation
- Æterna Zentaris Inc.
- Pfizer Inc.
- IntelGenx Technologies Corp.
- Ipsen S.A.
- Novartis International AG
- Antibe Therapeutics Inc.
- Bausch Health Companies Inc.
- Bayer AG
- Quest PharmaTech Inc.
- Bristol-Myers Squibb Company
- Endo Pharmaceuticals Inc.
- Kaken Pharmaceutical Co. Ltd.
- Impax Laboratories Inc.
- GemVax & KAEL Inc.
- Merck & Co. Inc.
- Kissei Pharmaceutical Co. Ltd.
- Abbott Laboratories
- Allium Medical Solutions Ltd.
- Asahi Kasei Corporation
- Asclepion Laser Technologies GmbH
- Boston Scientific Corporation
- Biolitec AG
- Coloplast A/S
- Eli Lilly and Company
- Endo International plc
- IPG Photonics Corporation
- KARL STORZ SE & Co. KG
- LISA Laser Products AG
- Medifocus Inc.
- Olympus Corporation
- Pharex Health Corporation
- PNN Medical A/S
- Quanta S.p.A.
For more information about this report visit https://www.researchandmarkets.com/r/td6lk4
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
